Monitoring glioblastoma patients using Apple Watch technology
Glioblastoma Remote Monitoring and Care - Research Protocol
This study is testing whether using an Apple Watch to track health data can help doctors better understand and care for patients with glioblastoma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Case Comprehensive Cancer Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Cleveland, Ohio) |
| Trial ID | NCT06129760 on ClinicalTrials.gov |
What this trial studies
This research focuses on utilizing the Apple Watch to monitor various health metrics such as walking data, heart rate, breathing rate, and sleep habits in patients with glioblastoma. The goal is to understand how these measurements correlate with the patients' symptoms and overall well-being. By analyzing this data, the study aims to develop proactive tools that can predict complications or changes in symptoms before they occur, ultimately improving patient care. The integration of wearable technology into clinical practice is particularly relevant in the context of increasing telehealth services.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have newly-diagnosed or recurrent glioblastoma and are undergoing treatment or active surveillance.
Not a fit: Patients under 18 years of age or those unable to provide informed consent due to language barriers or other conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of complications in glioblastoma patients, potentially improving survival rates.
How similar studies have performed: While the use of wearable technology in clinical settings is gaining traction, this specific application for glioblastoma monitoring is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * newly-diagnosed or recurrent glioblastoma undergoing treatment or active surveillance * at least 18 years of age at the time of study enrolment * Karnofsky Performance Status (KPS) ≥ 70% at time of study enrolment * able to comprehend informed consent form and provide informed consent * access to patient or caregiver's own Apple iPhone to interface with watch application for documentation of symptoms Exclusion Criteria: * under 18 years of age at the time of study enrolment * inability to give informed consent due to aphasia or other language barrier * tattoos located on the skin of the wrist or forearm where the Apple Watch will be placed or other skin conditions preventing adequate sensor function * inability to tolerate Apple Watch for at least 12 hours per day on at least 50% of days in a four-week period * no access to patient or caregiver Apple iPhone to document symptoms
Where this trial is running
Cleveland, Ohio
- Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center — Cleveland, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Andrew Dhawan, MD, DPhil — Brain Tumor Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center
- Study coordinator: Andrew Dhawan, MD, DPhil
- Email: dhawana@ccf.org
- Phone: 216-444-4272
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.